R10004 |
VX-809; Lumacaftor |
VX-809 (Lumacaftor) acts to correct CFTR mutations common in cystic fibrosis by
|
R10109 |
VX661 |
VX-661 is a second F508del CFTR corrector and is believed to help CFTR protein r
|
R10141 |
SB705498 |
SB705498 is a TRPV1 antagonist for hTRPV1, antagonizes capsaicin, acid, and heat
|
R10227 |
TAK438; Vonoprazan Fumarate |
Vonoprazan Fumarate (TAK-438) is a novel P-CAB (potassium-competitive acid block
|
R10266 |
GlyH101;GlyH-101 |
GlyH-101 is a cell-permeable glycinyl hydrazone compound that blocks CFTR with K
|
R10411 |
Ivacaftor;VX770 |
Ivacaftor (VX-770) is a potentiator of CFTR targeting G551D-CFTR and F508del-CFT
|
R10438 |
Dronedarone Hydrochloride |
Dronedarone HCl is a therapy for the treatment of patients with paroxysmal and p
|
R10439 |
Fasudil; HA-1077 |
HA-1077 inhibits vascular smooth muscle contraction by acting as an intracellula
|
R10487 |
PTC124 |
Ataluren (PTC124) selectively induces ribosomal read-through of premature but no
|
R10834 |
Vinpocetine |
Vinpocetine is a selective inhibitor of voltage-sensitive sodium channel for the
|
R10973 |
CB-5083 |
CB-5083 is a potent, selective, and orally bioavailable p97 AAA ATPase inhibitor
|